Head and Neck Cancer
CASE 6316
A Phase II Study of the Addition of Pembrolizumab to Postoperative Radiotherapy in Resected High Risk Cutaneous Squamous Cell Cancer of the Head and Neck.
View full trial information.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Leukemia, Acute Myeloid (AML)
PFIZ 2918
A Randomized (1:1), Double-Blind, Multi-Center, Placebo Controlled Study Evaluating Intensive Chemotherapy With Or Without Glasdegib (PF-04449913) Or Azacitidine (Aza) With Or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia.
View full trial information.
Multiple Myeloma
ROCH 1A18
A Phase Ib study of the safety and pharmacokinetics of atezolizumab (anti-pd-l1 antibody) alone or in combination with an immunomodulatory drug and/or daratumumab in patients with multiple myeloma (relapsed/refractory and post-autologous stem cell transplantation).
View full trial information.
Brain, Glioblastoma
CASE 3313
A prospective phase II trial of NovoTTF-100A with Bevacizumab (Avastin) in Patients with Recurrent Glioblastoma.
View full trial information.
Bladder Cancer, Breast Cancer, Colorectal Cancer, Melanoma, NSCLC (Non-small cell lung cancer), Prostate Cancer, Renal Cancer
CPI 1Y16
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers.
View full trial information.
All Cancer Types, Lymphoma
EAY 131
Molecular Analysis for Therapy Choice (MATCH).
View full trial information.
Search our Cancer Clinical Trials Database for a full listing of all open and accruing studies.
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access
Key learnings from DESTINY trials
Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors
Study of 401,576 patients reveals differences in cancer burdens as well as overall survival
Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy
